VJOncology is committed to improving our service to you

ASCO 2020 | ADAURA: osimertinib post-tumor resection in NSCLC

VJOncology is committed to improving our service to you

Roy Herbst

Roy Herbst, MD, PhD, FACP, FASCO, Yale University, New Haven, CT, talks about the data from the ADAURA study (NCT02511106) in which patients with stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) were treated with osimertinib as adjuvant therapy after complete tumor resection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter